Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.81
+0.05000.36%
Post-market: 13.830.0200+0.14%19:05 EDT
Volume:2.84M
Turnover:39.23M
Market Cap:10.71B
PE:-8.67
High:14.08
Open:13.46
Low:13.36
Close:13.76
52wk High:30.98
52wk Low:12.55
Shares:775.37M
Float Shares:130.76M
Volume Ratio:0.93
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5932
EPS(LYR):-1.4439
ROE:-270.95%
ROA:-148.15%
PB:19.61
PE(LYR):-9.56

Loading ...

Earning Preview: Summit Therapeutics PLC this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Earnings Agent
·
Yesterday

Kalshi to Allow Bets on Clinical Trials, FDA Decisions

Reuters
·
Jul 16

Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

Dow Jones
·
Jul 16

Summit Therapeutics Schedules Q2 2026 Results, Operational Update Call

Reuters
·
Jul 16

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal

Simply Wall St.
·
Jul 15

Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil

MT Newswires Live
·
Jul 14

Summit Therapeutics Signs Agreement to Sell Phase Iii Asset Ridinilazole to Biossil, Inc.

THOMSON REUTERS
·
Jul 14

Summit Therapeutics - to Receive $500,000 Upfront and up to $104.5 Mln in Milestones Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?

Simply Wall St.
·
Jun 25

UK Vehicle Production Rebounds in May, Halting Four-Month Decline

Deep News
·
Jun 25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 22

Summit Therapeutics shareholders approve 8 million-share increase to 2020 stock incentive plan

Reuters
·
Jun 13

Summit Therapeutics Co-CEO Mahkam Zanganeh reports purchase of 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics co-CEO Robert W. Duggan acquires 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics Withdraws Public Offering Due to Market Conditions

MT Newswires Live
·
Jun 11

Summit Therapeutics withdraws proposed underwritten public offering

TIPRANKS
·
Jun 11

BUZZ-Summit Therapeutics rebounds after pulling stock offering

Reuters
·
Jun 11

BRIEF-Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing

Reuters
·
Jun 11

Summit Therapeutics - No Securities to Be Sold in Proposed Underwritten Public Offering - SEC Filing

THOMSON REUTERS
·
Jun 11

Summit Therapeutics Stock Slides to 52-Week Low on Plans for Secondary Offering

Dow Jones
·
Jun 11